References
- Bathe S.K., Hiss M., Lichtinghagen R., Kielstein J.T.: A missed opportunity – consequences of unknown levetiracetam pharmacokinetics in a peritoneal dialysis patient. BMC Nephrology, 2014, 15: 49. www.biomedcentral.com/1471-2369/15/49.
- Cawello W.: Clinical Pharmacokinetic and Pharmacodynamic Profile of Lacosamide. Clin. Pharmacokinet., 2015, 54: 901– 914. doi: 10.1007/s40262-015-0276-0.
- Cawello W., Fuhr U., Hering U., Maatouk H., Halabi A.: Impact of Impaired Renal Function on the Pharmacokinetics of the Antiepileptic Drug Lacosamide. Clin. Pharmacokinet., 2013, 52: 897–906. doi: 10.1007/s40262-013-0080-7.
- Company-Albir M.J., Ruiz-Ramos J., Solana Altabella A., Marqués-Minana M.R., Vicent C., Poveda J.L.: Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report. J. Clin. Pharm. Ther., 2017, 42: 774–775. doi: 10.1111/jcpt.12568.
- Franquiz M.J., Kalaria S.N., Armahizer M.J., Gopalakrishnan M., McCarthy P.J., Badjatia N.: Lacosamide Pharmacokinetics in a Critically Ill Patient Receiving Continuous Venovenous Hemofiltration. Pharmacother. J. Hum. Pharmacol. Drug Ther., 2018, 38: e17–e21. doi: 10.1002/phar.2063.
- Jacob S., Nair A.B.: An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs R. D., 2016, 16: 303–306. doi: 10.1007/s40268-016-0148-6.
- Le Noble J.L.M.L., Foudraine N.A., Kornhips F.H.M., van Dam D.G.H.A., Neef C., Janssen P.K.C.: Extracorporeal Clearance of Levetiracetam During Continuous Venovenous Hemofiltration in a critically Ill Patient and New Dosing Recommendation. J. Clin. Pharmacol., 2017, 57: 536–537. doi: 10.1002/jcph.844.
- Louie J.M., Raphael K.L., Barker B.: Levetiracetam Use with Continuous Renal Replacement Therapy. Ann. Pharmacother., 2015, 49:1079–1080. doi: 10.1177/1060028015591845.
- Nei S.D., Beam W.B., Kashani K.B., Wieruszewski P.M.: Lacosamide Use with Intermittent Hemodialysis. Ann. Pharmacother., 2019, 53: 323–324. doi: 10-1177/1060028018808579.
- Nei S.D., Wittwer E.D., Kashani K.B., Frazee E.N.: Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation. Pharmacotherapy, 2015, 35: e127-e130. doi: 10.1002/phar.1615.
- New A.M., Nei S.D., Kashani K.B., Rabinstein A.A., Frazee E.N.: Levetiracetam Pharmacokinetics During Continuous Venovenous Hemofiltration and Acute Liver Dysfunction. Neurocrit. Care, 2016, 25: 141–144. doi: 10.1007/s12028-016-0242-1.
- Patsalos P.N.: Clinical Pharmacokinetics of Levetiracetam. Clin. Pharmacokinet, 2004, 43: 707–724. doi: 0312-5963/04/0011-0707/S31.00/0.
- Ratté M.T., Barker B.C., Middleton E., Johnson S.A.: Levetiracetam Use in Peritoneal Dialysis. Ann. Pharmakother., 2018, 52: 942–943. doi: 10.1177/106002801877016.
- Shive H.J., Tylor M., Sands K.A.: Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis. Ann. Pharmacother., 2017, 51, 862–865. doi: 10.1177/1060028017713294.
- Smetana K.S., Cook A.M., Thompson Bastin M.L., Oyler D.R.: Antiepileptic dosing for critically ill adult patients receiving renal replacemtn therapy. J. Crit. Care, 2016, 36: 116–124. doi: 10.1016/j.jcrc.2016.06.023.
- Van Matre E.T., Mueller S.W., Fish D.N., MacLaren R., Cava L.F., Neumann R.T., Kiser T.H.: Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing continuous Veno-Venous Hemofiltration. Am. J. Case Rep., 2017; 18: 458–462. doi: 10.12659/AJCR.902709.
- Wieruszewski P.M., Kashani K.B., Rabinstein A.A., Frazee E.: Levetiracetam Pharmacokinetics in a Critically Ill Anephric Patient on Intermittent Hemodialysis. Neurocrit. Care, 2018a, 28: 243–246. doi: 10.1007/s12028-017-0441-4.
- Wieruszewski P.M., Lopez-Ruiz A., Albright R.C., Fugate J.E., Barreto E.F.: Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. J. Pharm. Pract., 2018b, (ahead of print) doi: 10.1177/0897190018803765.